Thomas A. Bock, MD, MBA
About Thomas A. Bock, MD, MBA
Thomas Bock, MD, MBA, serves as the Chief Executive Officer of Notable Labs, a company focused on advancing precision medicine in oncology, particularly through the Predictive Precision Medicine Platform (PPMP) to enhance treatment protocols such as the Volasertib Phase 2 program for acute myeloid leukemia.
Thomas Bock Chief Executive Officer
Thomas Bock serves as the Chief Executive Officer of Notable Labs. His personal experiences with cancer in his family profoundly influence his understanding of the disease and his dedication to Notable's mission. Bock is committed to advancing Notable's patient-focused goals, which are central to the company's approach in developing treatments that address critical medical needs.
Thomas Bock Education and Expertise
Thomas Bock holds both a Medical Doctorate (MD) and a Master of Business Administration (MBA). This unique combination of clinical and business expertise enables him to effectively lead Notable Labs. Bock's leadership skills are instrumental in driving forward the company's initiatives, including the strategic in-licensing of compounds like Volasertib and leveraging advanced technologies such as the Predictive Precision Medicine Platform (PPMP).
Volasertib Phase 2 Program at Notable Labs
Under Thomas Bock's leadership, Notable Labs is advancing the Volasertib Phase 2 program targeting relapsed/refractory acute myeloid leukemia (r/r AML). Volasertib, a PLK-1 inhibitor, has shown activity in AML and other tumor types. The Phase 2 trial design includes a non-selective dose optimization phase, predicted to commence in Q2 2024, with initial data expected by Q4 2024. The program leverages Notable’s PPMP to identify responsive patient cohorts, aiming to enhance clinical outcomes and streamline the drug development process.
Predictive Precision Medicine Platform at Notable Labs
Thomas Bock oversees the utilization of Notable’s Predictive Precision Medicine Platform (PPMP), a cutting-edge technology designed to identify clinically responding patients. The PPMP has demonstrated a 100% accurate prediction of clinical trial outcomes, notably eliminating the need for a 30-patient cohort in the Volasertib program. This platform is integral to the anticipated success of the Phase 2 trial for Volasertib, targeting r/r AML, and is expected to set the stage for efficient and effective therapeutic developments.
Thomas Bock Welcomes New Board Directors
As CEO, Thomas Bock welcomed new Board Directors to Notable Labs. These industry leaders bring extensive experience from founding, leading, financing, and selling revolutionary biopharmaceutical and life sciences companies. Their expertise is expected to play a vital role in guiding Notable Labs’ strategic direction and enhancing its operational effectiveness in developing innovative cancer treatments.